vs
Mission Produce, Inc.（AVO）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Mission Produce, Inc.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.5倍（$319.0M vs $207.3M），Mission Produce, Inc.净利率更高（5.0% vs -62.0%，领先67.0%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -10.0%），Mission Produce, Inc.自由现金流更多（$55.6M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 11.0%）
根据现有信息，该描述将Mission Produce, Inc.错误混淆为一家日本电子游戏企业。原描述提及这家企业由前IREM员工于1990年4月6日创立，曾为艾尼克斯、哈德森开发多款游戏，作品覆盖街机、超级任天堂、Nintendo 64、PlayStation等多个平台。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
AVO vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $319.0M | $207.3M |
| 净利润 | $16.0M | $-128.6M |
| 毛利率 | 17.5% | — |
| 营业利润率 | 8.8% | -54.7% |
| 净利率 | 5.0% | -62.0% |
| 营收同比 | -10.0% | 25.9% |
| 净利润同比 | -7.5% | 3.5% |
| 每股收益（稀释后） | $0.23 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $319.0M | $207.3M | ||
| Q3 25 | $357.7M | $159.9M | ||
| Q2 25 | $380.3M | $166.5M | ||
| Q1 25 | $334.2M | $139.3M | ||
| Q4 24 | $354.4M | $164.6M | ||
| Q3 24 | $324.0M | $139.5M | ||
| Q2 24 | $297.6M | $147.0M | ||
| Q1 24 | $258.7M | $108.8M |
| Q4 25 | $16.0M | $-128.6M | ||
| Q3 25 | $14.7M | $-180.4M | ||
| Q2 25 | $3.1M | $-115.0M | ||
| Q1 25 | $3.9M | $-151.1M | ||
| Q4 24 | $17.3M | $-133.2M | ||
| Q3 24 | $12.4M | $-133.5M | ||
| Q2 24 | $7.0M | $-131.6M | ||
| Q1 24 | $0 | $-170.7M |
| Q4 25 | 17.5% | — | ||
| Q3 25 | 12.6% | — | ||
| Q2 25 | 7.5% | — | ||
| Q1 25 | 9.4% | — | ||
| Q4 24 | 15.7% | — | ||
| Q3 24 | 11.4% | — | ||
| Q2 24 | 10.4% | — | ||
| Q1 24 | 11.1% | — |
| Q4 25 | 8.8% | -54.7% | ||
| Q3 25 | 5.9% | -106.9% | ||
| Q2 25 | 1.8% | -64.8% | ||
| Q1 25 | 2.8% | -102.6% | ||
| Q4 24 | 8.1% | -74.3% | ||
| Q3 24 | 5.2% | -94.6% | ||
| Q2 24 | 4.1% | -79.1% | ||
| Q1 24 | 3.1% | -151.9% |
| Q4 25 | 5.0% | -62.0% | ||
| Q3 25 | 4.1% | -112.8% | ||
| Q2 25 | 0.8% | -69.0% | ||
| Q1 25 | 1.2% | -108.5% | ||
| Q4 24 | 4.9% | -80.9% | ||
| Q3 24 | 3.8% | -95.7% | ||
| Q2 24 | 2.4% | -89.5% | ||
| Q1 24 | — | -156.8% |
| Q4 25 | $0.23 | $-1.28 | ||
| Q3 25 | $0.21 | $-1.81 | ||
| Q2 25 | $0.04 | $-1.17 | ||
| Q1 25 | $0.05 | $-1.57 | ||
| Q4 24 | $0.25 | $-1.34 | ||
| Q3 24 | $0.17 | $-1.40 | ||
| Q2 24 | $0.10 | $-1.52 | ||
| Q1 24 | $0.00 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $64.8M | $421.0M |
| 总债务越低越好 | $95.8M | — |
| 股东权益账面价值 | $587.3M | $-80.0M |
| 总资产 | $983.0M | $1.5B |
| 负债/权益比越低杠杆越低 | 0.16× | — |
8季度趋势，按日历期对齐
| Q4 25 | $64.8M | $421.0M | ||
| Q3 25 | $43.7M | $202.5M | ||
| Q2 25 | $36.7M | $176.3M | ||
| Q1 25 | $40.1M | $127.1M | ||
| Q4 24 | $58.0M | $174.0M | ||
| Q3 24 | $49.5M | $150.6M | ||
| Q2 24 | $46.2M | $480.7M | ||
| Q1 24 | $39.9M | $112.3M |
| Q4 25 | $95.8M | — | ||
| Q3 25 | $131.5M | — | ||
| Q2 25 | $147.2M | — | ||
| Q1 25 | $117.9M | — | ||
| Q4 24 | $113.7M | — | ||
| Q3 24 | $134.4M | — | ||
| Q2 24 | $170.2M | — | ||
| Q1 24 | $156.1M | — |
| Q4 25 | $587.3M | $-80.0M | ||
| Q3 25 | $568.7M | $9.2M | ||
| Q2 25 | $552.3M | $151.3M | ||
| Q1 25 | $550.8M | $144.2M | ||
| Q4 24 | $547.3M | $255.0M | ||
| Q3 24 | $527.3M | $346.8M | ||
| Q2 24 | $513.3M | $432.4M | ||
| Q1 24 | $505.1M | $140.3M |
| Q4 25 | $983.0M | $1.5B | ||
| Q3 25 | $1.0B | $1.2B | ||
| Q2 25 | $1.0B | $1.3B | ||
| Q1 25 | $997.8M | $1.3B | ||
| Q4 24 | $971.5M | $1.5B | ||
| Q3 24 | $959.9M | $1.5B | ||
| Q2 24 | $966.9M | $1.6B | ||
| Q1 24 | $937.5M | $1.3B |
| Q4 25 | 0.16× | — | ||
| Q3 25 | 0.23× | — | ||
| Q2 25 | 0.27× | — | ||
| Q1 25 | 0.21× | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | 0.25× | — | ||
| Q2 24 | 0.33× | — | ||
| Q1 24 | 0.31× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $67.2M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $55.6M | $-100.8M |
| 自由现金流率自由现金流/营收 | 17.4% | -48.6% |
| 资本支出强度资本支出/营收 | 3.6% | 0.5% |
| 现金转化率经营现金流/净利润 | 4.20× | — |
| 过去12个月自由现金流最近4个季度 | $37.2M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $67.2M | $-99.8M | ||
| Q3 25 | $34.4M | $-91.4M | ||
| Q2 25 | $-11.8M | $-108.3M | ||
| Q1 25 | $-1.2M | $-166.5M | ||
| Q4 24 | $38.0M | $-79.3M | ||
| Q3 24 | $42.5M | $-67.0M | ||
| Q2 24 | $3.4M | $-77.0M | ||
| Q1 24 | $9.5M | $-190.7M |
| Q4 25 | $55.6M | $-100.8M | ||
| Q3 25 | $22.6M | $-92.7M | ||
| Q2 25 | $-25.0M | $-110.7M | ||
| Q1 25 | $-16.0M | $-167.8M | ||
| Q4 24 | $31.1M | $-79.5M | ||
| Q3 24 | $34.9M | $-68.6M | ||
| Q2 24 | $-4.4M | $-79.0M | ||
| Q1 24 | $-400.0K | $-193.9M |
| Q4 25 | 17.4% | -48.6% | ||
| Q3 25 | 6.3% | -58.0% | ||
| Q2 25 | -6.6% | -66.5% | ||
| Q1 25 | -4.8% | -120.5% | ||
| Q4 24 | 8.8% | -48.3% | ||
| Q3 24 | 10.8% | -49.2% | ||
| Q2 24 | -1.5% | -53.7% | ||
| Q1 24 | -0.2% | -178.2% |
| Q4 25 | 3.6% | 0.5% | ||
| Q3 25 | 3.3% | 0.8% | ||
| Q2 25 | 3.5% | 1.5% | ||
| Q1 25 | 4.4% | 1.0% | ||
| Q4 24 | 1.9% | 0.1% | ||
| Q3 24 | 2.3% | 1.2% | ||
| Q2 24 | 2.6% | 1.4% | ||
| Q1 24 | 3.8% | 3.0% |
| Q4 25 | 4.20× | — | ||
| Q3 25 | 2.34× | — | ||
| Q2 25 | -3.81× | — | ||
| Q1 25 | -0.31× | — | ||
| Q4 24 | 2.20× | — | ||
| Q3 24 | 3.43× | — | ||
| Q2 24 | 0.49× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVO
| Avocado | $256.9M | 81% |
| Blueberry | $36.5M | 11% |
| Mango | $18.7M | 6% |
| Other | $6.9M | 2% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
